← Back to Search


Thrombolytic Therapy for Ischemic Stroke

Phase 1 & 2
Research Sponsored by Baylor College of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Anterior Circulation stroke within the last six hours
Posterior Circulation stroke within the last 12 hours
Screening 3 weeks
Treatment Varies
Follow Up ninety days
Awards & highlights

Study Summary

This trial is testing the use of a GP IIb/IIIa inhibitor (abciximab) in patients with stroke.

Who is the study for?
This trial is for adults who've had a stroke affecting the brain's anterior region within 6 hours or posterior region within 12 hours. They must not have signs of non-ischemic causes like hemorrhage or tumor, severe kidney/liver issues, very low platelet counts, or be at high risk of bleeding.Check my eligibility
What is being tested?
The study tests how well GP IIb/IIIa inhibitors work in patients with ischemic strokes. These are potent platelet inhibitors already used for heart conditions and might help when given alongside standard treatments like t-PA or thrombectomy.See study design
What are the potential side effects?
Potential side effects may include increased risk of bleeding due to the drug's ability to prevent blood clots. This could lead to complications such as bruising easily, nosebleeds, and in rare cases more serious internal bleeding.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I had a stroke affecting the front part of my brain within the last 6 hours.
I had a stroke in the back part of my brain within the last 12 hours.
I am 18 years old or older.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~ninety days
This trial's timeline: 3 weeks for screening, Varies for treatment, and ninety days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Ninety day functional outcomes

Trial Design

1Treatment groups
Experimental Treatment
Group I: Measurement of Platelet functionExperimental Treatment1 Intervention
Patients with ischemic stroke may be given alteplase or other thrombolytic. Additionally, patients may be given IV platelet inhibitors and subjected to thrombectomy. Platelet functions are measured after intervention.
First Studied
Drug Approval Stage
How many patients have taken this drug
Thrombolytic Agent

Find a Location

Who is running the clinical trial?

Baylor College of MedicineLead Sponsor
1,002 Previous Clinical Trials
6,002,754 Total Patients Enrolled
4 Trials studying Stroke
1,198 Patients Enrolled for Stroke

Media Library

Thrombolytic Agent (Anti-thrombotic) Clinical Trial Eligibility Overview. Trial Name: NCT05415150 — Phase 1 & 2
Stroke Research Study Groups: Measurement of Platelet function
Stroke Clinical Trial 2023: Thrombolytic Agent Highlights & Side Effects. Trial Name: NCT05415150 — Phase 1 & 2
Thrombolytic Agent (Anti-thrombotic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05415150 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many subjects are participating in this experiment?

"Affirmative. Per information on clinicaltrials.gov, this research study is presently accepting participants. Originally posted in February 18th 2022 and last updated June 8th 2022, the trial needs to enlist 30 volunteers from 1 site."

Answered by AI

Are there any remaining vacancies for this medical trial?

"According to clinicaltrials.gov, this research is currently seeking participants - the initial posting being on February 18th 2022 and the most recent update occurring June 8th 2022."

Answered by AI

Who else is applying?

What state do they live in?
What site did they apply to?
Michael E. DeBakey VA Medical Center
What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?
~9 spots leftby May 2025